Clinical trial · Observational
Postoperative Adjuvant TACE Treatment in CK18 Positive Patients
The Effect of Postoperative Adjuvant TACE Treatment in CK18 Positive Patients of Hepatocellular Carcinoma.
NCT02724345CI-TRIAL-00021571completedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
To evaluate and analyse the clinical effect and application value of postoperative adjuvant TACE treatment in patients with different expression levels of CK18 using randomized controlled study and provide evidence for the necessity of postoperative adjuvant TACE.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Hepatocellular Carcinoma. | Hepatocellular Carcinoma | ONTOLOGY_EXACT | 0.98 |
| Postoperative Adjuvant TACE | — | UNRESOLVED | — |
Interventions
Interventions (0)
Data not yet available
No intervention recorded.
Design
Arms and outcomes
Arms (2)
- label
- CK18 positive
- description
- HCC patients with CK18 high expression levels in tumor tissue.
- label
- CK18 negative
- description
- HCC patients with CK18 high expression levels in tumor tissue.
Primary outcomes (1)
- measure
- Overall survival
- timeFrame
- 3 years
Secondary outcomes (1)
- measure
- Time to recurrence
- timeFrame
- 3 years
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 70 Years
Show eligibility criteria text
Inclusion Criteria: 1. Via clinical diagnosis and confirm it is primary liver cancer 2. Pathological evidence of HCC 3. Estimate tumor can gain treatment of curing operation 4. No evidence for extrahepatic metestasis 5. liver function ：Child-Pugh A/B Exclusion Criteria: 1. reject to attend； 2. impossible to come to our hospital for physical examination regularly. 3. cancer epitome、seed focus、lymph node or distant metastasis 4. Blood clotting function hindrance; 5, Patients with other diseases which may affect the treatment mentioned.
References
Publications (0)
Data not yet available
No reference posted for this study.